A single study has gone a long way toward changing clinical practices.
I'm at the American Thoracic Society annual meeting for the next couple of days, learning what's new in critical care, pulmonary and sleep m...
Restoring corticosteroid sensitivity in patients with chronic obstructive pulmonary disease (COPD) may holds promise for effectively treatin...
We're having a curtailed winter and early spring here in the inland Northwest, or so it seems. We could still get a snowstorm or 2, but the ...
Chronic respiratory disease is projected to be the third most common cause of death by 2020, but it currently underestimated. This year's American Thoracic Society meeting focuses on issues to bring them to the attention of the rest of the medical
Updated guidelines for chronic obstructive pulmonary disease revised the definition and staging of the condition, and an expert offers tips for optimal care.
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a new intravenous drug for bacterial skin and
This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease.
Recalls, warnings, and approvals.
This regulatory update covers approval of a combined long-term maintenance treatment for chronic obstructive pulmonary disease, warnings against driving after taking insomnia drugs and on use of migraine drugs in pregnant women, and more.